Status: Recruiting
RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
This project proposes to establish a prospective, multicenter, randomized, controlled clinical study to compare the safety and efficacy of Intralesional Rituximab Injection versus Involved Site Radiation Therapy for the treatment of primary ocular adnexal MALT lymphoma. The aim is to provide high-level clinical evidence for the treatment of ocular adnexal MALT lymphoma and to offer patients treatment options that have fewer complications and comparable therapeutic effects.
Participants needed: 108
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Zhongshan Ophthalmic Center, Sun Yat-sen UniversityUpdated: Apr 20, 2026Locations: 1
Eligibility criteria
Age between 18 to 75 years old. [+3]
Based on the TNM staging of ocular adnexal lymphoma (Table 1), patients staged a... [+10]